SCHEMBL22609269

SCHEMBL22609269

CCOC(=O)c1nnsc1Cc1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ILK Q13418 1/20 0.47
▸ ALDH1A1 P00352 6/20 0.46
▸ MAPT P10636 5/20 0.46
▸ KDM4E B2RXH2 5/20 0.46
▸ LMNA P02545 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ HPGD P15428 2/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ ALOX12 P18054 1/20 0.46
▸ CCR6 P51684 1/20 0.46
▸ HKDC1 Q2TB90 1/20 0.46
▸ KDM4C Q9H3R0 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HTT P42858 1/20 0.44
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ TRPM8 Q7Z2W7 1/20 0.44
▸ PKM P14618 1/20 0.43
▸ MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23453738 0.87 ILK (0.47) ILKALDH1A1MAPTKDM4EMEN1
SCHEMBL23486286 0.86 ILK (0.59) ILKALDH1A1MAPTKDM4ELMNA
SCHEMBL23486284 0.85 ILK (0.54) ILKALDH1A1MAPTMEN1KMT2A
SCHEMBL22609346 0.83 ILK (0.52) ILKALDH1A1MAPTKDM4EHPGD
SCHEMBL23453737 0.81 MAPT (0.43) ILKALDH1A1MAPTKDM4ELMNA
SCHEMBL22609302 0.80 ALDH1A1 (0.44) ALDH1A1MAPTLMNAKMT2AHPGD
SCHEMBL22609219 0.76 KMT2A (0.46) ALDH1A1MAPTKDM4ELMNAMEN1
SCHEMBL24101218 0.75 L3MBTL1 (0.48) ILKALDH1A1MAPTKDM4ELMNA
SCHEMBL22609328 0.75 ILK (0.77) ILKALDH1A1MAPTKDM4ELMNA
SCHEMBL22609340 0.74 MAPT (0.46) ALDH1A1MAPTKDM4ELMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF ORFAN BIOTECH SL (ES) 2021-06-10 — — US disclosed
EP-3731840-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF Orfan Biotech Inc. (US) 2020-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171503-A1 GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF PNPO, XDH, GLS ILK 3208/4885ALDH1A1 149/4885MAPT 2376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback